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Background/Aims
Impaired esophageal motility and disrupted esophagogastric junction (EGJ) on high-resolution manometry (HRM) have been 
associated with increased reflux severity in gastroesophageal reflux disease (GERD) patients. However, there are limited data evaluating 
HRM parameters in proton pump inhibitors (PPI) non-responders.
Methods
Clinical and endoscopic data, HRM and multichannel intraluminal impedance-pH studies performed of PPI therapy in patients with 
typical GERD symptoms were reviewed from 3 international centers. Frequency of GERD symptoms was assessed on and off PPI 
therapy in both non-responders (< 50% symptom improvement on PPI therapy) and responders. Rome IV definitions identified 
non-erosive reflux disease, reflux hypersensitivity, and functional heartburn. Univariate and multivariate analyses were performed to 
determine predictors of non-response. 
Results
Of 204 patients, 105 were PPI non-responders and 99 were responders. Non-responders showed higher EGJ contractile integral 
values, and a lower frequency of type II and III EGJ morphology (P ≤ 0.03 for each comparison). Esophageal body diagnoses on HRM 
(fragmented peristalsis, ineffective esophageal motility, or absent peristalsis) did not predict non-response. On multivariate analysis, 
non-pathological acid exposure time (OR, 2.5; 95% CI, 1.2-5.0; P < 0.001), normal mean nocturnal baseline impedance values (OR, 
2.7-2.4; 95% CI, 1.0-6.1; P < 0.05), normal EGJ contractile integral values (OR, 3; 95% CI, 1.3-7.4; P = 0.012), and presence of type I 
EGJ morphology (OR, 1.9; 95% CI, 1.0-3.4; P = 0.044) were associated with an unfavorable response to PPIs.
Conclusions
Intact EGJ metrics on HRM complement normal reflux burden in predicting non-response to PPI therapy. HRM has value in the 
evaluation of PPI non-responders.
(J Neurogastroenterol Motil 2020;26:447-454)
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Introduction  
Gastroesophageal reflux disease (GERD), defined by the 
presence of esophageal and extra-esophageal symptoms due to 
pathological reflux of gastric content, represents one of the most 
common gastrointestinal disorders, with an increasing worldwide 
prevalence.1-3 However, as many as 40% of patients with GERD 
symptoms report an unsatisfactory response to acid suppression 
with proton pump inhibitor (PPI) therapy,4,5 and evaluating patho-
physiology and mechanisms of symptom generation are critical to 
further investigation of these patients.
With the development of high-resolution manometry (HRM), 
more specific evaluation of esophageal motor function has expanded 
our knowledge of inter-relationships with GERD.6,7 HRM also 
allows precise characterization of esophagogastric junction (EGJ) 
morphology and identification of hiatus hernia.8 The esophago-
gastric junction contractile integral (EGJ-CI) is a HRM tool that 
assesses EGJ barrier function,9 and low EGJ-CI is associated with 
abnormal total and supine acid burden.10 Abnormal EGJ morphol-
ogy is associated with a higher probability of positive multichannel 
intraluminal impedance pH (MII-pH) monitoring compared to 
normal EGJ morphology, and both EGJ morphology and EGJ-CI 
independently predict esophageal reflux burden.11
While EGJ disruption or dysfunction is a primary pathophysi-
ologic factor in determining reflux occurrence, esophageal body 
motor function influences duration of contact of the refluxate with 
the esophageal mucosa. Consequently, impaired esophageal peristal-
sis may account for delayed bolus transit and reduced esophageal 
reflux clearance in patients with GERD.12 Early studies using 
conventional manometry demonstrated higher prevalence of low 
amplitude (< 30 mmHg) or non-transmitted esophageal body 
contractions in GERD patients, and these motility abnormalities 
increase in parallel with the severity of GERD.13,14 For instance, the 
presence of large breaks in esophageal peristaltic integrity on HRM 
is associated with significantly prolonged supine reflux clearance, 
higher acid exposure time (AET), and erosive esophagitis.15 Large 
breaks are often identified in the context of suspected GERD-relat-
ed chronic cough,16,17 the presence of which can be associated with 
suboptimal benefit from antireflux therapy.16 Finally, failed swallows, 
which represent panesophageal breaks in peristaltic integrity, predict 
abnormal AET better than ineffective swallows without long breaks 
in peristaltic integrity.8
Despite these advances in assessment of esophageal motor 
function, no studies have evaluated HRM parameters in PPI non-
responders. The present investigation is a multicenter, observational 
study aimed at evaluating and comparing HRM parameters be-
tween PPI responders and non-responders in patients with GERD 
symptoms. 
Materials and Methods  
Patients
Adult patients (age > 18 years) with suspected GERD evalu-
ated with HRM and 24-hour MII-pH monitoring at 3 centers (2 
in Europe and 1 in the United States) over a 2-year period (2017-
2019) for symptoms unresponsive to acid suppressive therapy 
or prior to anti-reflux surgery were eligible for inclusion in this 
retrospective observational cohort study. Further inclusion crite-
ria consisted of the presence of dominant esophageal symptoms 
(heartburn, regurgitation, and chest pain),18 ambulatory MII-pH 
studies performed off acid-suppressive therapy (at least 7 days phar-
macological wash-out),19 and 10 acceptable supine water swallows 
for HRM analysis using Chicago classification version 3.0 (CC 
v3.0).20 Patients with inadequate studies (equipment malfunction, 
poor study quality, and artifacts) and/or incomplete HRM studies 
were excluded. Patients with achalasia spectrum disorders (inte-
grated relaxation pressure > 15 mmHg), connective tissue disease, 
history of neoplasia and prior foregut surgery were also excluded. 
The study protocol was approved by the Institutional Review Board 
of the 3 University Centers (IRB No. 201607083), and each col-
laborating institution completed data sharing agreements for analy-
sis of deidentified demographic, clinical, MII-pH and HRM data. 
Written informed consent was obtained from all patients.
While esophageal symptoms were required for study inclusion, 
the presence of extra-esophageal symptoms (chronic cough, asthma, 
hoarseness, and globus) was also recorded. Symptom frequency 
(based on number of symptom episodes/week) of esophageal symp-
toms was assessed before and after at least 8 weeks of standard dose 
PPI therapy (Esomeprazole 40 mg once daily [od], Pantoprazole 
40 mg od, Lansoprazole 30 mg od, and Omeprazole 20 mg od) 
within the previous year on validated institutional self-report Likert 
scales on patient questionnaires at each study site.21-24 Patients were 
categorized as non-responders if symptom improvement while on 
therapy, using these scales, was < 50% compared to symptom as-
sessment off therapy.25
Esophageal High-resolution Manometry
A catheter with 36 circumferential solid state pressure sensors, 
449
Esophageal Motility and PPI Refractoriness
Vol. 26, No. 4   October, 2020 (447-454)
located at 1-cm intervals (Medtronic, Minneapolis, MN, USA) 
was inserted, after an overnight fast, through an anesthetized nostril 
such that at least 3 distal pressure sensors positioned in the stomach. 
The manometric study was performed using ten 5 mL swallows of 
ambient temperature fluid at 30-second intervals in a semi-recum-
bent position.26 
Each HRM study was evaluated using the following CC 
v3.0 criteria20: (1) intact swallow: distal contractile integral (DCI) 
> 450 mmHg∙cm∙sec; (2) fragmented swallow: DCI > 450 
mmHg∙cm∙sec with > 5 cm breaks; (3) weak swallow: DCI 
100-450 mmHg∙cm∙sec; AND (4) failed swallow: DCI < 100 
mmHg∙cm∙sec. CC v3.0 diagnoses consisted of the following: (1) 
fragmented peristalsis: ≥ 50% fragmented swallows; (2) ineffective 
esophageal motility (IEM): ≥ 50% of any combination of weak or 
failed swallows; and (3) absent contractility: 100% failed swallows. 
EGJ barrier function and morphology were recorded. EGJ-CI was 
evaluated by recording the EGJ barrier vigor (using a DCI like 
tool) during a period of quiet rest over exactly 3 respiratory cycles, 
and divided by the duration of the respiratory cycles to make the 
metric independent of respiration. EGJ-CI was considered low 
when < 39.1 mmHg∙cm.8,9
EGJ morphology was determined by the relationship between 
lower esophageal sphincter (LES) and crural diaphragm; type I 
when LES and crural diaphragm were superimposed, type II when 
separated < 3 cm, and type III when separated ≥ 3 cm.7
24-Hour Multichannel Intraluminal Impedance pH 
Monitoring
MII-pH was recorded using a 2.3 mm diameter polyvinyl 
catheter assembly containing a series of impedance electrodes, each 
4 mm in axial length, spaced at 2-cm intervals, and a distal antimo-
ny pH electrode (Sandhill Scientific Inc, Highlands Ranch, CO, 
USA). The pH electrodes were calibrated using pH 4.0 and pH 
7.0 buffer solutions before pH-impedance monitoring. Following 
HRM, the MII-pH assembly was passed through the anesthetized 
nostril, and positioned with the pH electrode 5 cm above the LES, 
and impedance electrodes at 3, 5, 7, 9, 15, and 17 cm proximal to 
the LES. Event markers, corroborated with paper diaries, were 
used to record symptoms, meal times, and supine periods. AET 
was defined as pathological if the time pH < 4 exceeded 6% of the 
total recording time,19,27 and non-pathologic if < 6%. Reflux-symp-
tom association was assessed using symptom association probability 
(SAP) for all reflux episodes using previously described methodol-
ogy.28 Mean nocturnal baseline impedance (MNBI) was calculated 
by measuring baseline impedance values at 3 cm and 5 cm above 
LES, across stable nocturnal 10-minute periods (at or around 1, 2, 
and 3 AM). The values from the 3 time periods for both levels were 
averaged to yield the mean nocturnal baseline impedance (MNBI) 
for each channel. Values < 2292 Ω defined abnormal studies. 29
Gastroesophageal Reflux Disease Phenotypes
Endoscopy negative patients with abnormal AET were defined 
as having non-erosive reflux disease (NERD).30 In the context of 
esophageal symptoms, patients with normal AET but positive SAP 
were diagnosed as reflux hypersensitivity (RH), and those with nor-
mal AET and negative SAP were classified as functional heartburn 
(FH).27,30
Statistical Methods
Data are presented as mean ± standard deviation. Compari-
sons between groups were assessed using the Fisher’s exact test. 
Group means were compared using ANOVA with Bonferroni 
correction. Odds ratios (ORs) with 95% confidence intervals (CI) 
were calculated to assess the association between AET, MNBI at 
3 cm and 5 cm above the LES, EGJ-CI, EGJ morphology, and 
the PPI response. Multivariate regression models were generated 
to evaluate if HRM and 24-hour MII-pH parameters were inde-
pendent predictors for PPI response or non-response. Significance 
was achieved when the P-value was < 0.05. Statistical analysis was 




A total of 204 patients with esophageal symptoms fulfilled in-
clusion criteria and formed the study cohort (Table 1). Among the 
included patients, 105 (54%) non-responders to prior PPI therapy 
while 99 (46%) were responders; these did not differ in terms of 
sex, age, and body mass index. Extra-esophageal symptoms were 
reported by approximately a third of both non-responders and re-
sponders, with similar proportions of chronic cough (24% vs 30%, 
respectively), asthma (6% vs 4%), hoarseness (10% vs. 11%), and 
globus (6% vs 5%, P > 0.05 for each comparison). A total of 21 
patients had erosive reflux disease (ERD) (15 grade A, 5 grade B, 
and 1 grade C according to Los Angeles classification). Proportions 
of ERD patients and endoscopically identified hiatus hernia were 
also similar (Table 1). 
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Multichannel Intraluminal Impedance pH Data in 
Non-responders and Responders
Esophageal acid burden, as measured by AET and MNBI, 
was lower in non-responders (Table 2). Non-responders demon-
strated significantly lower mean total and supine AET compared to 
responders (P ≤ 0.03 for each comparison), despite similar mean 
upright AET values (P = 0.229). MNBI values at both the 3 cm 
and 5 cm locations were significantly higher in non-responders (P 
≤ 0.03 for each comparison). Non-responders and responders re-
ported similar numbers of reflux episodes (P= 0.347).
High-resolution Manometry Data in Non-responders 
and Responders
Non-responders demonstrated significantly higher mean basal 
LES pressure and EGJ-CI values compared to responders (P ≤ 
0.03 for each comparison), while mean integrated relaxation pres-
sure values were comparable between the 2 groups (P = 0.438). 
Table 1. Demographic and Clinical Characteristics in Non-respond-








Male/female 46/59 43/56 0.891
Age (yr) 50 (21.1) 47 (18.3) 0.807
BMI (kg/m2) 23.1 (1.9) 22.4 (2.1) 0.774
Presence of atypical  
symptoms
36 (34%) 29 (29%) 0.452
Erosive esophagitis 10 (9%) 11 (11%) 0.816
Hiatal hernia 19 (18%) 16 (16%) 0.847
BMI, body mass index.
Data are presented as number, mean (SD), or number (%).
Table 2. Esophageal Physiologic Test Results in Responders and 
Non-responders








  AET (%) 4.2 (1.3) 7.8 (2.4) 0.034
  Upright AET (%) 6.2 (2.1) 6.7 (2.3) 0.225
  Supine AET (%) 2.1 (0.9) 9.0 (3.4) 0.003
  Reflux episodes 51 (17) 64 (23) 0.344
  MNBI 3 cm (Ω) 2108 (412) 1607 (235) 0.027
  MNBI 5 cm (Ω) 2057 (436) 1654 (258) 0.024
HRM
  Basal LES pressure (mmHg)
23.7 (3.3) 20.4 (2.8) 0.033
  EGJ-CI (mmHg∙cm) 30 (4.2) 22 (2.1) 0.011
  IRP (mmHg) 8.2 (1.5) 7.7 (1.2) 0.448
  DCI (mmHg∙cm∙sec) 1641 (158) 1236 (116) 0.029
  Absent peristalsis 7 (7%) 8 (8%) 0.789
  DES 1 (1%) 0 (0.%) 0.884
  Fragmented peristalsis 10 (9%) 5 (5%) 0.278
  IEM 11 (10%) 15 (15%) 0.402
  Normal peristalsis 76 (73%) 71 (72%) 0.896
MII-pH, multichannel intraluminal impedance pH; AET, acid expo-
sure time; MNBI, mean nocturnal baseline impedance; HRM, high-
resolution manometry; LES, lower esophageal sphincter; EGJ-CI, 
esophagogastric junction contractile integral; IRP, integrated relax-
ation pressure; DCI, distal contractile integral; DES, distal esopha-
geal spasm; IEM, ineffective esophageal motility.

















Figure. Proportion of responders and non-responders in patients 
with Type I, II, and III esophagogastric junction (EGJ). There were 
statistically more non-responders among patients with Type 1 EGJ. In 
contrast, with EGJ disruption, the likelihood of response was statisti-
cally higher, indirectly indicating that the presence of EGJ disruption 
was a marker for abnormal reflux burden.
Table 3. Multivariate Logistic Regression Analysis of Predictors of 
Proton Pump Inhibitors Non-response
Predictors of PPIs non-response OR (95% CI) P-value
   AET < 6% 2.5 (1.2-5.0) 0.011
   Number of reflux episodes 1.3 (0.6-2.9) 0.608
   MNBI 3 cm > 2292 Ω 2.7 (1.0-6.1) 0.047
   MNBI 5 cm > 2292 Ω 2.4 (1.0-5.6) 0.046
   EGJ-CI > 39.1 mmHg∙cm 3 (1.3-7.1) 0.012
   Type I EGJ 1.8 (1.0-3.4) 0.047
   IEM 1.8 (0.7-5.2) 0.225
   Fragmented peristalsis 0.5 (0.2-1.6) 0.324
   Absent peristalsis 0.7 (0.4-2.7) 0.778
PPIs, proton pump inhibitors; AET, acid exposure time; MNBI, 
mean nocturnal baseline impedance; EGJ-CI, esophagogastric junc-
tion contractile integral; IEM, ineffective esophageal motility.
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Mean DCI values were significantly higher in non-responders 
compared to responder patients (P = 0.029). Proportions of 
patients with absent peristalsis, distal esophageal spasm (DES), 
fragmented peristalsis and IEM were comparable between non-
responders and responders (P ≥ 0.3 for each comparison) (Table 2).
There was a significantly lower frequency of type II and III 
EGJ morphology in non-responders compared to responders (31% 
and 36% vs 17% and 21%, respectively; P < 0.01) (Figure). 
On univariate analysis, non-pathologic AET (OR [95% CI], 
3 [1.5-5.9]; P = 0.001), normal MNBI values at both the 3 cm 
and 5 cm locations (OR [95% CI], 1.9 [1.1-3.1]; P = 0.041 and 
1.8 [1.1-2.9]; P = 0.043), normal EGJ-CI values (OR [95% 
CI]: 3.4 [1.4-8.0]; P = 0.006), and type I EGJ morphology were 
independent predictors of non-response to PPI (OR [95% CI], 
1.9 [1.0-3.4], P = 0.046). In contrast, presence of type II and III 
EGJ was associated with a significantly higher probability of PPI 
response (OR [95% CI], 2 [1.4-2.7]; P < 0.01). 
On multivariate analysis, non-pathologic AET, normal MNBI 
values at both 3 cm and 5 cm above the LES, normal EGJ-CI val-
ues and presence of type I EGJ morphology were associated with 
non-response to PPIs (Table 3). On the other hand, pathologic 
AET, abnormal MNBI at both 3 cm and 5 cm above the LES, 
abnormally low EGJ-CI values and presence of type II-III EGJ 
morphology were associated with PPI response (Table 3).
Gastroesophageal Reflux Disease Phenotypes
Among the 183 endoscopy-negative patients, 50 (27%) were 
phenotyped as NERD according to MII-pH findings. Fifty-six 
(31%) had RH, and the remaining 77 patients (42%), with normal 
AET and negative SAP, were characterized as FH. Sixteen patients 
out of the 105 non-responders (15%) and 34 patients out of the 99 
responders (34%) fulfilled criteria for NERD (P = 0.002).
Mean basal LES pressure, EGJ-CI and DCI values were 
significantly lower in ERD and NERD compared to FH and in 
RH patients, but other HRM parameters did not differ among the 
3 groups. In the NERD and ERD group, a significantly higher 
proportion of patients had evidence of esophageal body hypomotil-
ity features (absent peristalsis, fragmented peristalsis, and IEM) 
compared to FH (P ≤ 0.003 for each comparison, Table 4).
Discussion  
In this observational, international multicenter study, we dem-
onstrate that esophageal HRM is more likely to show intact EGJ 
metrics in non-responders to acid suppressive therapy, suggesting 
that the generation of esophageal symptoms occur without evidence 
of abnormal GERD pathophysiology at the EGJ. In contrast, 
abnormal EGJ morphology and barrier function were strongly 
associated with PPI response, indicating that these features are 
primary HRM markers of abnormal reflux burden in the esopha-
gus. Indeed, similar EGJ disruption is demonstrated in patients 
with characteristics of NERD, in contrast to FH. We conclude 
that evaluation of esophageal motor function, and interpretation of 
HRM using CC v3.0 as well as novel EGJ metrics is useful in the 
investigation of PPI non-responders. 
We made efforts to select a large group of patients with 
Table 4. High-resolution Manometry Findings in ERD, NERD, RH and FH patients
HRM findings ERD (n = 21) NERD (n = 50) RH (n = 56) FH (n = 77)
Basal LES pressure (mmHg) 20.8 (2.4)a 20.9 (2.5)a 28.6 (3.2) 29.4 (2.8)
EGJ-CI (mmHg∙cm) 17.5 (4.9)a 21.0 (4.5)a 30.6 (5.9) 32.4 (6.6)
IRP (mmHg) 6.8 (1.2) 7.1 (1.1) 8.2 (1.5) 9.1 (1.9)
DCI (mmHg∙cm∙sec) 1246 (123)a 1123 (128)a 1769 (158) 1989 (201)
Absent peristalsis 4 (19%)b 6 (12%)b 4 (7%) 1 (1%)
DES 0 (0%) 0 (0%) 1 (2%) 0 (0%)
Fragmented peristalsis 2 (10%)b 9 (18%)b 3 (5%) 1 (1%)
IEM 4 (19%)a 9 (18%)a 8 (15%)a 3 (4%)
Normal peristalsis 30 (55%) 26 (52%) 38 (71%) 72 (94%)
aP < 0.05 vs functional heartburn (FH).
bP < 0.01 vs FH.
HRM, high-resolution manometry; ERD, erosive reflux disease; NERD, non-erosive reflux disease; RH, reflux hypersensitivity; LES, lower 
esophageal sphincter; EGJ-CI, esophagogastric junction contractile integral; IRP, integrated relaxation pressure; DCI, distal contractile integral; 
DES, distal esophageal spasm; IEM, ineffective esophageal motility.
Data are presented as mean (SD) or number (%). 
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esophageal symptoms across multiple centers in order to evaluate a 
representative patient cohort, with meticulous characterization into 
responders and non-responders based on patient questionnaires 
and therapeutic outcome evaluation. Indeed, our designation into 
responder status appears appropriate, since responders had higher 
AET as well as lower MNBI, both features that have been docu-
mented to predict treatment response.31-33 While it is conceivable 
that non-responders may have had higher proportions of weakly 
acid reflux episodes, the overall proportions of reflux episodes were 
similar between responders and non-responders (Table 2). There-
fore, it is more likely that non-responders may have non-reflux 
mechanisms of symptom generation.34
Our findings demonstrate that PPI non-responders have a 
higher likelihood of having intact EGJ barrier function, and intact 
esophageal body contraction vigor, compared to responders. We 
demonstrate a higher likelihood of PPI response in the presence of a 
hiatus hernia (EGJ morphology types II and III), which is a known 
marker for abnormal esophageal reflux burden compared to normal 
EGJ morphology (type I EGJ, no hiatus hernia).8 Our findings 
therefore concur with data that demonstrate that abnormal esopha-
geal acid burden predicts PPI response.35 Further, our MNBI data 
also supports the fact that abnormal values of MNBI at 3 cm and 5 
cm above the LES are characterized by a favorable response to ac-
id-suppressive therapy.33 The EGJ-CI is a novel HRM tool that is 
gaining acceptance as a metric for assessment of EGJ barrier func-
tion. This has been demonstrated to be associated with abnormal 
reflux burden, especially when esophageal body evaluation shows 
IEM, since IEM is another HRM metric that predicts abnormal 
reflux burden.36 Supporting these conclusions, non-responders in 
our study demonstrate higher basal LES pressure, EGJ-CI, and 
DCI mean values, as well as lower total and supine mean AET 
values. Consistent with previous reports, the manometric finding of 
a hiatus hernia (EGJ morphology types II and III, 44% of patients) 
was higher than the endoscopic recording of a hiatus hernia (17% of 
patients, P < 0.01). It is now well recognized that HRM is more 
accurate than endoscopy in the identification of a hiatus hernia,37,38 
which adds to the value of HRM in the context of GERD, par-
ticularly since our data and other reports demonstrate that a mano-
metric hiatus hernia is predictive of abnormal reflux burden,36,39 and 
our current findings show a higher proportion of PPI responders 
with a manometric hiatus hernia.
While EGJ disruption or dysfunction is a primary pathophysi-
ologic factor in determining reflux occurrence, esophageal body 
motor function influences duration of contact of the refluxate with 
the esophageal mucosa. Consequently, impaired esophageal peri-
stalsis may account for delayed bolus transit and reduced esopha-
geal reflux clearance in patients with GERD.9 Large breaks are 
often identified in the context of suspected GERD-related chronic 
cough,16,17 the presence of which can be associated with suboptimal 
benefit from antireflux therapy.16 Finally, failed swallows, which 
represent panesophageal breaks in peristaltic integrity, predict ab-
normal AET better than ineffective swallows without long breaks in 
peristaltic integrity.10 In this study, we did not identify any of these 
esophageal body motor findings as predictors of PPI non-response.
Our results also show that mean basal LES pressure and EGJ-
CI values were significantly lower in ERD and NERD patients 
compared to FH and in RH patients. Moreover, a significantly 
higher proportion of esophageal body hypomotility (fragmented 
peristalsis, IEM, and absent contractility) was also observed in 
these cohorts compared to FH. This supports the argument 
that the modern definition of NERD, which requires abnormal 
esophageal reflux burden in addition to absence of erosive disease, 
demonstrates abnormal EGJ and esophageal body motor charac-
teristics that have been shown to be associated with abnormal reflux 
burden. This is consistent with existing evidence that suggests that 
PPI non-response may be a marker for non-GERD mechanisms 
of symptom generation,34 wherein motor features associated with 
GERD pathophysiology are identified less often, and MII-pH 
demonstrates features of FH. Our findings support the classifica-
tion of motor findings proposed by the GERD consensus group, 
where hierarchical reporting of EGJ and esophageal body motor 
features is recommended in HRM studies performed in the context 
of GERD.7
To our knowledge, this is the first study evaluating the role of 
the HRM parameters and their association with PPI response in 
a large series of responders and non-responders. Strengths of the 
present study are the number of patients included and rigorous 
selection process. However, some limitations temper the strength 
of our findings, the predominant limitation relating to retrospec-
tive patient identification and data analysis for the purpose of this 
multicenter study, despite the fact that data collection was pro-
spectively performed independent of the current study across the 
3 sites. Questionnaire data can be subject to recall bias. Patients 
were evaluated after at least 8-week PPI treatment, however some 
patients have been evaluated after a longer period of standard dose 
PPI therapy. Additional psychological and psychosocial factors 
influencing symptom presentation and PPI non-response, as well 
as alternate medications (such as neuromodulators) contributing 
to symptom response were not addressed. Moreover, it is well es-
tablished that multiple factors contribute to non-response, and our 
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designation of non-response could have been biased by patient re-
lated factors that were not evaluated in this study. Finally, we could 
not address further outcome following the performance of these 
esophageal tests and due to the retrospective nature of the study. 
Nevertheless, despite these limitations, our results demonstrate the 
value of assessing esophageal motor function in patients with per-
sisting esophageal symptoms, and identify a clear role for HRM in 
these clinical settings. 
In summary, our results demonstrate that impaired esophageal 
function on HRM associates with increased reflux burden, and 
consequently, a better response to PPI therapy. On the other hand, 
patients not responding to acid suppressive therapy are character-
ized by a less severe reflux burden and better HRM metrics, im-
plying a non-GERD mechanism for symptom persistence. These 
results lead to the conclusion that HRM should be performed and 
taken into account before subjecting patients with symptoms sug-
gestive of GERD to anti-reflux therapies, and that the future itera-
tion of the CC should incorporate this information in the context of 
assessment of patients with GERD.
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